Subventions et des contributions :

Titre :
The coalescent process in genetics : mapping complex diseases and other applications
Numéro de l’entente :
RGPIN
Valeur d'entente :
100 000,00 $
Date d'entente :
10 mai 2017 -
Organisation :
Conseil de recherches en sciences naturelles et en génie du Canada
Location :
Québec, Autre, CA
Numéro de référence :
GC-2017-Q1-03062
Type d'entente :
subvention
Type de rapport :
Subventions et des contributions
Informations supplémentaires :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2022-2023)

Nom légal du bénéficiaire :
Larribe, Fabrice (Université du Québec à Montréal)
Programme :
Programme de subventions à la découverte - individuelles
But du programme :

The coalescent process, a stochastic process used to simulate population genealogies, has attracted much attention during then past fifteen years, mostly due to the numerous applications in human genetics research. We have introduced a method that uses the coalescent process with recombination (Larribe et al., 2002, Larribe, 2004), in order to estimate the location of a genetic mutation influencing a disease, i.e. in order to do genetic fine mapping. Using a composite-conditional-likelihood strategy (Larribe and Lessard, 2008) on "windows" of genetic markers, we have improved the stability of the estimates and greatly increased the number of genetic markers usable by the method. Then, we have further developed the approach in the context of complex genetic diseases, by devising methods for estimating haplotypes and causal alleles from phenotypes and genotypes (Larribe et al., 2015); moreover, the method is now able to take into account genetic models allowing incomplete penetrance and phenocopy. It is still common practice in the genetics world to base the analysis on thousands of association statistics, each for a pair of genetic markers, and thus to ignore the dependence between individuals and the spatial genetic dependency between markers. Therefore, in our proposal we continue the difficult task of offering a refined solution to this problem by addressing both dependency issues mentioned above. In contrast with many other approaches, our method is not based on testing association, but is a genetic mapping methodology based on the likelihood; as such, it incorporates rich genetic models.
We propose to extend our research program by allowing more complex genetic models, exhibiting interaction between genes and by considering multiple rare variants; we also want to be able to treat quantitative traits and to implement the method at the genome scale. Finally, in order to analyze the vast amount of data generated today in molecular biology, we propose to use our expertise in composite likelihood combined with innovative methods to build genealogies. As a great number of genetic diseases are still a mystery to geneticists, the impact of the development of such advanced mapping methods should be important for future medical research.